Literature DB >> 6330606

Similar anticonvulsant, but unique, behavioural effects of opioid agonists in the seizure-sensitive Mongolian gerbil.

R J Lee, J G Bajorek, P Lomax.   

Abstract

Opioid agonists were used to investigate the modulation of seizures mediated by mu, kappa and delta opiate receptors in the seizure-sensitive Mongolian gerbil. Morphine (1.0-25 mg/kg, s.c.) were used as prototypic agonists for mu, kappa and delta opiate receptors. Each opioid decreased the incidence and severity of the seizure as compared to control values. The anticonvulsant effects of morphine (10 mg/kg, s.c.) and ketocyclazocine (0.5 mg/kg, s.c.) were reversed by naloxone (1.0 mg/kg, s.c.), while the anticonvulsant effects of N-allylnormetazocine (2 mg/kg, s.c.) were not significantly changed by naloxone. Additionally, abnormal behavior was observed following administration of the opioids. Morphine (10 mg/kg, s.c.) produced excitation and hyperresponsiveness with intermittent cataleptic-like states. Ketocyclazocine (10 mg/kg, s.c.) predominantly produced a stuporous, immobile state, accompanied by some loss of posture. N-allylnormetazocine (10 mg/kg, s.c.) produced ataxia and stereotypic side-to-side head nodding . Naloxone was able to reverse the behavioral effects produced by morphine and ketocyclazocine but not those produced by N-allylnormetazocine. The data presented are consistent with earlier studies which demonstrated the anticonvulsant effects of beta-endorphin in the gerbil. This study further suggests that opioids have a protective role against seizure activity in the gerbil and the opioid anticonvulsant effect is not specific to one type of opioid agonist.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6330606     DOI: 10.1016/0028-3908(84)90024-8

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  12 in total

1.  Developmental and regional alteration of kappa-opioid receptors in seizure-susceptible EL mouse brain.

Authors:  T Kai; H Onishi; S Koide; M Katayama; S Yamagami
Journal:  Neurochem Res       Date:  1998-02       Impact factor: 3.996

2.  Influence of coat color genes on seizure behavior in Mongolian gerbils.

Authors:  P Gray-Allan; R Wong
Journal:  Behav Genet       Date:  1990-07       Impact factor: 2.805

3.  Cerebral ischemia in gerbils: effects of acute and chronic treatment with adenosine A2A receptor agonist and antagonist.

Authors:  D K Von Lubitz; R C Lin; K A Jacobson
Journal:  Eur J Pharmacol       Date:  1995-12-20       Impact factor: 4.432

4.  Endogenous methionine enkephalin may play an anticonvulsant role in the seizure-susceptible El mouse.

Authors:  S Koide; H Onishi; M Katayama; S Yamagami
Journal:  Neurochem Res       Date:  1993-12       Impact factor: 3.996

5.  Effects of morphine and D-Ala2-D-Leu5-enkephalin in the seizure-susceptible El mouse.

Authors:  S Koide; H Onishi; S Yamagami; Y Kawakita
Journal:  Neurochem Res       Date:  1992-08       Impact factor: 3.996

6.  Effects of naloxone on seizure latencies of black (a/a) Mongolian gerbils (Meriones unguiculatus).

Authors:  R Wong; P Gray-Allan
Journal:  Behav Genet       Date:  1991-09       Impact factor: 2.805

7.  HPLC/RIA analysis of bioactive methionine enkephalin content in the seizure-susceptible El mouse brain.

Authors:  S Koide; H Onishi; M Katayama; T Kai; S Yamagami
Journal:  Neurochem Res       Date:  1995-09       Impact factor: 3.996

8.  Metabolic profile of opioid peptides differs in the hippocampus and striatum of seizure-susceptible E1 mice.

Authors:  S Koide; H Onishi; M Katayama; S Yamagami
Journal:  Neurochem Res       Date:  1995-03       Impact factor: 3.996

9.  Chronic administration of adenosine A3 receptor agonist and cerebral ischemia: neuronal and glial effects.

Authors:  D K Von Lubitz; R C Lin; M Boyd; N Bischofberger; K A Jacobson
Journal:  Eur J Pharmacol       Date:  1999-02-19       Impact factor: 4.432

10.  Reduction of postischemic brain damage and memory deficits following treatment with the selective adenosine A1 receptor agonist.

Authors:  D K Von Lubitz; M Beenhakker; R C Lin; M F Carter; I A Paul; N Bischofberger; K A Jacobson
Journal:  Eur J Pharmacol       Date:  1996-04-29       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.